Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol
| Autor: | A H Sutor, V Mall, K B Thomas |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
Asparaginase Adolescent Hemorrhage chemistry.chemical_compound Germany Acute lymphocytic leukemia Antineoplastic Combined Chemotherapy Protocols medicine Humans Risk factor Child Glucocorticoids Retrospective Studies business.industry Vascular disease Incidence Incidence (epidemiology) Thrombosis Retrospective cohort study Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Surgery chemistry Child Preschool Pediatrics Perinatology and Child Health business Subclavian vein |
| Zdroj: | Klinische Pädiatrie. 211:201-204 |
| ISSN: | 1439-3824 0300-8630 |
| DOI: | 10.1055/s-2008-1043788 |
| Popis: | A multi-center retrospective survey was conducted to evaluate the incidence and types of hemostatic complications occurring in children with acute lymphoblastic leukemia (ALL) during treatment according to the ALL-BFM-90 treatment protocol. All of the BFM-treatment centers (n = 77) were approached and a 95% response rate with information on 1100 patients was obtained. Thrombotic or bleeding episodes occurred in 31 patients (2.8%), 19 of whom had thrombosis and 12 bleeding complications, involving the central nervous system (42%), the subclavian vein (29%), the gastro-intestinal tract, skin, lower extremities or pelvis (29%). Recovery was noted in 28 of 31 patients, while 3 died as a result of hemostatic complications. Bleeding or thrombosis occurred in patients receiving prophylactic substitution with plasma or plasma-derived concentrates (n = 16) as well as in those without substitution (n = 13). The majority of hemostatic complications (90%) occurred during the induction therapy of the treatment protocol, in particular during the period which included simultaneous administration of glucocorticoids and E. coli L-asparaginase. The concurrent administration of E. coli L-asparaginase and glucocorticoids may be an additional risk factor for thromboembolic events during therapy according to the ALL-BFM-90 protocol. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|